Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.

Lee, Mi Hyun; Gu, Gi Hong; Lee, Ji Eun; Oum, Boo Sub

doi:2011.52.7.816

J Korean Ophthalmol Soc > Volume 52(7); 2011 > Article

Original Article

Journal of the Korean Ophthalmological Society 2011;52(7):816-824.
DOI: https://doi.org/10.3341/jkos.2011.52.7.816 Published online July 15, 2011.

Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.

Mi Hyun Lee, Gi Hong Gu, Ji Eun Lee, Boo Sub Oum

Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea. jlee@pusan.ac.kr

삼출성 나이관련황반변성과 결절맥락막혈관병증에서 광역학치료와 베바시주맙 병합치료

이미현⋅구기홍⋅이지은⋅엄부섭

Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea

Abstract

PURPOSE
To compare the efficacies of photodynamic therapy (PDT) using verteporfin combined with intravitreal bevacizumab in choroidal neovascularization secondary to age-related macular degeneration and polypoidal choroidal vasculopathy (PCV). METHODS: Photodynamic therapy followed by 3 monthly intravitreal injections of bevacizumab were performed for neovascular age-related macular degeneration (AMD group) and PCV (PCV group). The injections were performed within 2 weeks after PDT and then every 4 to 6 weeks. During the 12-month follow-up period, best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT), and number of reinjections were reviewed retrospectively. RESULTS: Out of 38 eyes, there were 21 eyes in the AMD group (mean age 66.8 years old) and 17 eyes in the PCV group (mean age 66.4 years old). The average follow-up duration was 17.0 months. At 12 months, the BCVA (logMAR) improved from 0.75 at baseline to 0.49 in the AMD group (p = 0.01) and from 0.81 to 0.63 in the PCV group (p = 0.03). The CSMT decreased significantly from 329 to 231 in the AMD group and from 354 to 223 in the PCV group. At 12 months, 20 eyes (95.2%) in the AMD group and 15 eyes (88.2%) in the PCV group increased or maintained BCVA. The numbers of reinjections were 4.3 in the AMD group and 3.0 in the PCV group. There were no significant differences in BCVA, BCVA changes, CSMT, or number of reinjection between the two groups. CONCLUSIONS: Combined PDT and intravitreal bevacizumab injections showed no significant difference in stabilization of vision or retreatment rates between neovascular age-related macular degeneration and PCV.

Key Words: Age-related macular degeneration;Bevacizumab;Choroidal neovascularization;Photodynamic therapy;Polypoidal choroidal vasculopathy